Stay updated with breaking news from Provide Earlier Availability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/CNW Telbec/ - Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of OPDIVO® (nivolumab) 360 mg every three weeks or 3mg/kg every two...
First new systemic therapy in more than 15 years for cancer related to asbestos exposure Today, Bristol Myers Squibb Canada announced Health Canada's approval of OPDIVO ® 360 mg every three weeks or 3mgkg every two weeks plus YERVOY ® 1 mgkg every six weeks for the treatment of adult patients with unresectable malignant pleural mesothelioma who have not received prior systemic therapy for MPM. i This is the ...